NCT06266585

Brief Summary

The objective of this retrospective, prospective, multicenter cohort study is to determine the risk factors for deterioration of CVT patients after admission and establish a scoring model for risk stratification of patients. This study included two stages, the first stage was to enroll CVT patients from a single center from 2017 to 2022 for modeling, and the second stage was to enroll CVT patients from three centers in 2023 for external validation

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
273

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Jan 2023

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2023

Completed
12 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2023

Completed
1 day until next milestone

Study Completion

Last participant's last visit for all outcomes

January 1, 2024

Completed
4 days until next milestone

First Submitted

Initial submission to the registry

January 5, 2024

Completed
2 months until next milestone

First Posted

Study publicly available on registry

February 20, 2024

Completed
Last Updated

February 20, 2024

Status Verified

February 1, 2024

Enrollment Period

12 months

First QC Date

January 5, 2024

Last Update Submit

February 16, 2024

Conditions

Outcome Measures

Primary Outcomes (3)

  • Number of Participants with CVT deteriorated on radiology

    One of the following situations occurs: new or progressive bleeding or infarction, midline displacement (\>3mm), increased cerebral edema, and placeholder effect by comparing the CT before and after; mRS and/or GCS decreased due to decreased consciousness, increased focal neurological impairment, new focal neurological impairment or death.

    After admission until discharge, a maximum of 30 days

  • Number of Participants with altered neurological function

    mRS Score decreased due to decreased consciousness, increased focal neurological impairment, new focal neurological impairment or death.

    After admission until discharge, a maximum of 30 days

  • Number of Participants with altered consciousness

    GCS Score decreased

    After admission until discharge, a maximum of 30 days

Secondary Outcomes (2)

  • Neurological function at 30th day after onset (mRS)

    30th day after onset

  • Emergency surgery rates

    After admission until discharge, a maximum of 30 days

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients with cerebral venous thrombosis (CVT)

You may qualify if:

  • Age≥ 18 years old
  • Patients were diagnosed with cerebral venous thrombosis (CVT) through imaging techniques such as Computed Tomography Venography (CTV), Magnetic Resonance Venography (MRV), or Digital Subtraction Angiography (DSA)
  • The diagnostic algorithm for CVT conformed to the current guideline criteria

You may not qualify if:

  • Patients who had performed endovascular treatment (EVT) or decompressive craniectomy (DC) before admission and those whose primary treatment was EVT or DC rather than conservative treatment after admission
  • Patients with severe hepatic or renal insufficiency
  • Patients with intracranial tumors
  • Patients with other cerebrovascular diseases

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Capital Medical University Affiliated Beijing Tiantan Hospital

Beijing, Beijing Municipality, China

Location

Related Publications (1)

  • Feng Y, Mo S, Li X, Jiang P, Wu J, Li J, Liu P, Wang S, Liu Q, Tong X. Development and validation of a score for clinical deterioration in patients with cerebral venous thrombosis. Neurosurg Rev. 2025 Jan 16;48(1):56. doi: 10.1007/s10143-025-03224-7.

MeSH Terms

Conditions

Intracranial Thrombosis

Condition Hierarchy (Ancestors)

Intracranial Embolism and ThrombosisCerebrovascular DisordersBrain DiseasesCentral Nervous System DiseasesNervous System DiseasesVascular DiseasesCardiovascular DiseasesThromboembolismEmbolism and Thrombosis

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
OTHER
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Director of Department of cerebrovascular Neurosurgery

Study Record Dates

First Submitted

January 5, 2024

First Posted

February 20, 2024

Study Start

January 1, 2023

Primary Completion

December 31, 2023

Study Completion

January 1, 2024

Last Updated

February 20, 2024

Record last verified: 2024-02

Locations